GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (STU:D05) » Definitions » Price-to-Free-Cash-Flow

Deciphera Pharmaceuticals (STU:D05) Price-to-Free-Cash-Flow : N/A (As of May. 27, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Deciphera Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2024-05-27), Deciphera Pharmaceuticals's share price is €23.20. Deciphera Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.63. Hence, Deciphera Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Deciphera Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

STU:D05's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 23.4
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Deciphera Pharmaceuticals's Free Cash Flow per Share for the three months ended in Mar. 2024 was €-0.58. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-1.63.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 26.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 9.60% per year.

During the past 9 years, Deciphera Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 26.60% per year. The lowest was -57.00% per year. And the median was -22.65% per year.


Deciphera Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for Deciphera Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals Price-to-Free-Cash-Flow Chart

Deciphera Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - - - -

Deciphera Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Deciphera Pharmaceuticals's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deciphera Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Deciphera Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



Deciphera Pharmaceuticals Price-to-Free-Cash-Flow Calculation

Deciphera Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=23.20/-1.63
=N/A

Deciphera Pharmaceuticals's Share Price of today is €23.20.
Deciphera Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.63.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Deciphera Pharmaceuticals  (STU:D05) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Deciphera Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Deciphera Pharmaceuticals (STU:D05) Business Description

Traded in Other Exchanges
Address
200 Smith Street, Waltham, MA, USA, 02451
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Deciphera Pharmaceuticals (STU:D05) Headlines

No Headlines